Relationship between history of aGVHD and immune cell subsets in blood at 3 months posttransplant.
. | No grade 2-4 aGVHD by day 100 . | Grade 2-4 aGVHD by day 100 . | P . |
---|---|---|---|
No. evaluated | 164* | 144* | |
Decreased among patients with a history of grade 2-4 aGVHD, n/μL (95% CI) | |||
γδTCR+ T cells | 14 (2-1682) | 7 (0-316) | <.001 |
BM | 11 (0-578) | 3 (0-315) | <.001 |
G-PB | 107 (0.1-715) | 9 (0-5120) | .22 |
B cells | 34 (0-932) | 8 (0-2014) | <.001 |
BM | 36 (0-571) | 2 (0-606) | <.001 |
G-PB | 33 (0-932) | 16 (0-2014) | .17 |
cDCs | 4 (0-101) | 2 (0-32) | .001 |
BM | 4 (0-39) | 3 (0-34) | <.001 |
G-PB | 5 (0-101) | 16 (0-2014) | .15 |
pDCs | 0.7 (0-36) | 0.4 (0-9) | <.001 |
BM | 0.8 (0-36) | 0.3 (0-6) | <.001 |
G-PB | 0.6 (0-15) | 0.4 (0-9) | .11 |
Not affected by a history of grade 2-4 aGVHD, n/μL (95% CI) | |||
Total T cells | 447 (0-3247) | 346 (0-2629) | .06 |
Total CD4+ T cells | 135 (0-994) | 114 (0-1210) | .52 |
Naive CD4+ T cells | 11 (0-282) | 9 (0-423) | .88 |
Effector memory CD4+ T cells | 32 (0-420) | 24 (0-583) | .53 |
Central memory CD4+ T cells | 59 (0-678) | 53 (0-584) | .33 |
Terminal effector CD4+ T cells | 2 (0-279) | 2 (0-86) | .67 |
CD4+ Tregs | 29 (0-693) | 41 (0-979) | .3 |
Total CD8+ T cells | 197 (0-1872) | 151 (0-1872) | .09 |
Naive CD8+ T cells | 35 (0-539) | 21 (0-1360) | .21 |
Effector memory CD8+ T cells | 28 (0-580) | 24 (0-580) | .09 |
Central memory CD8+ T cells | 53 (0-1197) | 38 (0-1168) | .06 |
Terminal effector CD8+ T cells | 32 (0-907) | 21 (0-1368) | .16 |
NK cells | |||
16+56+ double positive | 70 (0-1376) | 50 (0-395) | .3 |
16−56+ single positive | 46 (0-450) | 36 (0-610) | .54 |
. | No grade 2-4 aGVHD by day 100 . | Grade 2-4 aGVHD by day 100 . | P . |
---|---|---|---|
No. evaluated | 164* | 144* | |
Decreased among patients with a history of grade 2-4 aGVHD, n/μL (95% CI) | |||
γδTCR+ T cells | 14 (2-1682) | 7 (0-316) | <.001 |
BM | 11 (0-578) | 3 (0-315) | <.001 |
G-PB | 107 (0.1-715) | 9 (0-5120) | .22 |
B cells | 34 (0-932) | 8 (0-2014) | <.001 |
BM | 36 (0-571) | 2 (0-606) | <.001 |
G-PB | 33 (0-932) | 16 (0-2014) | .17 |
cDCs | 4 (0-101) | 2 (0-32) | .001 |
BM | 4 (0-39) | 3 (0-34) | <.001 |
G-PB | 5 (0-101) | 16 (0-2014) | .15 |
pDCs | 0.7 (0-36) | 0.4 (0-9) | <.001 |
BM | 0.8 (0-36) | 0.3 (0-6) | <.001 |
G-PB | 0.6 (0-15) | 0.4 (0-9) | .11 |
Not affected by a history of grade 2-4 aGVHD, n/μL (95% CI) | |||
Total T cells | 447 (0-3247) | 346 (0-2629) | .06 |
Total CD4+ T cells | 135 (0-994) | 114 (0-1210) | .52 |
Naive CD4+ T cells | 11 (0-282) | 9 (0-423) | .88 |
Effector memory CD4+ T cells | 32 (0-420) | 24 (0-583) | .53 |
Central memory CD4+ T cells | 59 (0-678) | 53 (0-584) | .33 |
Terminal effector CD4+ T cells | 2 (0-279) | 2 (0-86) | .67 |
CD4+ Tregs | 29 (0-693) | 41 (0-979) | .3 |
Total CD8+ T cells | 197 (0-1872) | 151 (0-1872) | .09 |
Naive CD8+ T cells | 35 (0-539) | 21 (0-1360) | .21 |
Effector memory CD8+ T cells | 28 (0-580) | 24 (0-580) | .09 |
Central memory CD8+ T cells | 53 (0-1197) | 38 (0-1168) | .06 |
Terminal effector CD8+ T cells | 32 (0-907) | 21 (0-1368) | .16 |
NK cells | |||
16+56+ double positive | 70 (0-1376) | 50 (0-395) | .3 |
16−56+ single positive | 46 (0-450) | 36 (0-610) | .54 |
Blood samples drawn 3 months posttransplant from patients with a history of grade 2-4 aGVHD had lower numbers of B cells, γδ TCR+ T cells, and DC subsets compared with patients without a history of grade 2-4 aGVHD.
CI, confidence interval.
Listed numbers of samples are for analysis of total T cells. Numbers of samples for analysis of other immune cell subsets were slightly less in some cases.